XML 28 R16.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company manages its business activities on a consolidated basis and operates as a single operating segment, R&D, which engages in the business of developing a new class of RNA-targeting therapeutics to treat a broad range of genetic diseases. The Company’s operations are primarily in the United States. The chief operating decision maker does not review assets in evaluating the results and therefore, such information is not presented.
The operating financial results of the Company’s R&D segment for the three and nine months ended September 30, 2025 and 2024 are as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenue$795 $— $3,150 $— 
Less: Significant segment expenses
Personnel-related expenses4,922 5,242 15,701 14,795 
Clinical and preclinical expenses4,313 4,589 13,502 13,283 
Facilities-related and overhead2,090 1,937 6,088 5,655 
Professional and consulting fees2,204 1,312 5,390 4,128 
Corporate expenses297 317 1,334 814 
Impairment of right-of-use asset494 — 494 — 
Travel and entertainment126 119 420 379 
Plus: Other segment (loss) income(1,448)32 (340)542 
Segment net loss$(15,099)$(13,484)$(40,119)$(38,512)